Research Studies

Study Title

Neuraltus NP001 Trial (Safety and Efficacy Study of NP001 in Patients With ALS and Systemic Inflammation)

Enrollment Status


Principal Investigators

Site-PI: Michael Benatar, MD, PhD

Study Type

Drug Trial


  • This is a 6 month randomized, double-blind, placebo-controlled study of NP001 in subjects with ALS and evidence of elevated systemic inflammation.


ALS patients


Click to Expand

Study Involvement

Click to Expand

Subjects will be allocated (1:1) to NP001 and placebo.
Drug or placebo will be given by intravenous administration for 5 consecutive days in Month 1 and for 3 consecutive days in Months 2 through 6.



Primary Funding Source

Neuraltus Pharmaceuticals, Inc

Related Publications

Click to Expand

No items found

Related Presentations & Lectures

Click to Expand

No items found